MYND Life Sciences Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MYNDF research report →
Companywww.myndsciences.com
MYND Life Sciences Inc. , a life sciences-based neuro-pharmaceutical drug development company, advances medicines based on neuro-anti-inflammatory substances for depressive disorders through science and clinical trials in Canada and the United States. It focuses on the analysis of psilocin and psilocybin extracts, and analogs.
- CEO
- Wilfred A. Jefferies
- IPO
- 2021
- HQ
- Kelowna, BC, CA
Price Chart
Valuation
- Market Cap
- $657.84K
- P/E
- -2.18
- P/S
- 0.00
- P/B
- -0.66
- EV/EBITDA
- -3.48
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 35.68%
- ROIC
- 91.43%
Growth & Income
- Revenue
- $92.99K · 0.00%
- Net Income
- $-1,517,860 · 57.45%
- EPS
- $-0.03 · 57.98%
- Op Income
- $-1,828,763
- FCF YoY
- 89.10%
Performance & Tape
- 52W High
- $0.07
- 52W Low
- $0.01
- 50D MA
- $0.01
- 200D MA
- $0.01
- Beta
- 0.96
- Avg Volume
- 4.39K
Get TickerSpark's AI analysis on MYNDF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our MYNDF Coverage
We haven't published any research on MYNDF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MYNDF Report →